Prescription drug for premature ejaculation moves closer to approval

The FDA has received a new drug application from ALZA Corp. for dapoxetine hydrochloride, a possible new treatment for premature ejaculation.

Related Content:

Drug Therapy

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria